Dr. Ku on Combinations and Sequencing of Treatments for Gastric Cancer

Geoffrey Y. Ku, MD
Published: Monday, Jan 23, 2017



Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combinations and sequencing of treatments for patients with gastric and esophageal cancers.

Patients getting the treatment in the third-line setting is too late, explains Ku. There are 10 other phase III studies that are evaluating treatment in the first- and second-line setting.

Another area of improvement is biomarker selection. Up until this point, the main biomarker has been PD-L1 expression on the tumor cells; however, it’s not perfect, Ku states. When PD-L1 is used as a biomarker, PD-L1–positive tumors respond approximately 25% of the time, whereas PD-L1–negative tumors respond 10% of the time.
 


Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combinations and sequencing of treatments for patients with gastric and esophageal cancers.

Patients getting the treatment in the third-line setting is too late, explains Ku. There are 10 other phase III studies that are evaluating treatment in the first- and second-line setting.

Another area of improvement is biomarker selection. Up until this point, the main biomarker has been PD-L1 expression on the tumor cells; however, it’s not perfect, Ku states. When PD-L1 is used as a biomarker, PD-L1–positive tumors respond approximately 25% of the time, whereas PD-L1–negative tumors respond 10% of the time.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x